Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy
A partir d'échantillons sanguins prélevés sur 37 patients atteints d'un carcinome du pancréas et recevant une chimiothérapie à base de gemcitabine entre 2009 et 2010, cette étude prospective évalue l'association entre les niveaux sanguins de cellules endothéliales circulantes, l'expression tumorale de facteurs pro-angiogéniques et la survie des patients
BACKGROUND:Pancreatic carcinoma is a significant cause of cancer-related death in developed countries. As the level of circulating endothelial cells (CECs) is known to increase in response to various cancers, we investigated the predictive potential of CEC levels and the association of these levels with the expression of proangiogenic factors in pancreatic carcinoma patients.METHODS:Pancreatic carcinoma patients receiving gemcitabine chemotherapy were prospectively assigned to this study. CEC levels were measured using the CellTracks system and the plasma levels of several angiogenesis factors were measured by an enzyme-linked immunosorbent assay and multiplex immunoassay. Associations between clinical outcomes and the levels of these factors were evaluated.RESULTS:Baseline CEC levels were markedly higher in pancreatic carcinoma patients than in healthy volunteers. Moreover, these high CEC levels were associated with decreased overall survival (median, 297 days versus 143 days, P < 0.001) and progression-free survival (median, 150 days versus 64 days, P = 0.008), as well as with high vascular endothelial growth factor, interleukin (IL)-6, IL-8, and IL-10 expression levels in these patients.CONCLUSIONS:Several chemokines and proangiogenic factors promote the release of CEC, and the levels of CEC may be a useful prognostic marker in pancreatic carcinoma patients undergoing gemcitabine-based chemotherapy.
BMC Cancer , article en libre accès, 2011